Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leronlimab - CytoDyn

Next Previous
Drug Profile

Leronlimab - CytoDyn

Alternative Names: PA-14; PRO-140; Vyrologix®

Latest Information Update: 24 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Progenics Pharmaceuticals
  • Developer CytoDyn; Progenics Pharmaceuticals; Syneos Health
  • Class Anti-inflammatories; Antidementias; Antineoplastics; Antiretrovirals; Antivirals; Hepatoprotectants; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Triple negative breast cancer
  • Preregistration COVID 2019 infections; HIV infections
  • Phase II Colorectal cancer; Inflammation; Non-alcoholic steatohepatitis; Post acute COVID 19 syndrome; Solid tumours
  • Phase I Alzheimer's disease
  • Preclinical Glioblastoma
  • Suspended COVID-19 pneumonia
  • Discontinued Graft-versus-host disease; HIV-1 infections; Multiple sclerosis; Stroke; Traumatic brain injuries

Most Recent Events

  • 20 Feb 2026 Pharmacodynamics data from a preclinical trial in Triple-negative-breast-cancer released by CytoDyn
  • 27 Jan 2026 CytoDyn initiates a expanded access trial for Triple-negative-breast-cancer
  • 16 Oct 2025 CytoDyn completes a phase II/III in HIV-1 infections (Treatment-experienced) in the US (SC, Injection) (NCT03902522)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top